KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Goodwill (2022 - 2025)

Castle Biosciences' Goodwill history spans 3 years, with the latest figure at $10.7 million for Q2 2024.

  • For Q2 2024, Goodwill changed N/A year-over-year to $10.7 million; the TTM value through Jun 2024 reached $10.7 million, changed N/A, while the annual FY2023 figure was $10.7 million, 0.0% changed from the prior year.
  • Goodwill for Q2 2024 was $10.7 million at Castle Biosciences, roughly flat from $10.7 million in the prior quarter.
  • Across five years, Goodwill topped out at $10.7 million in Q4 2022 and bottomed at $10.7 million in Q4 2022.
  • The 3-year median for Goodwill is $10.7 million (2022), against an average of $10.7 million.
  • The largest YoY upside for Goodwill was 0.0% in 2023 against a maximum downside of 0.0% in 2023.
  • A 3-year view of Goodwill shows it stood at $10.7 million in 2022, then changed by 0.0% to $10.7 million in 2023, then changed by 0.0% to $10.7 million in 2024.
  • Per Business Quant, the three most recent readings for CSTL's Goodwill are $10.7 million (Q2 2024), $10.7 million (Q4 2023), and $10.7 million (Q4 2022).